Adjuvant Nivolumab as Standard of Care in Resected Bladder Cancer

Extended follow-up from the CheckMate 274 trial further supports adjuvant nivolumab as a standard of care for patients with resected muscle-invasive urothelial carcinoma.
Medscape Medical News

source https://www.medscape.com/viewarticle/988496?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?